Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Dr Enrico Vanni, a Non-Executive Director of the Company, yesterday purchased 75,000 ordinary shares of 25 pence each in the Company (“Ordinary Shares”) at an average price of 64.7 pence per Ordinary Share. Following […]

Advanced Oncotherapy (AVO) – Update on Harley Street and Sinophi

Advanced Oncotherapy – Update on Harley Street and Sinophi Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the building work for the Harley Street site is expected to start in early January with completion of the building works expected by March 2018. ‎This follows the successful planning permission […]

Advanced Oncotherapy (AVO) – Appointment of Joint Broker

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Stifel Nicolaus Europe Limited as Joint Broker to the Company, with immediate effect. Stockdale Securities remains Nominated Adviser to the Company. Advanced Oncotherapy Plc www.avoplc.com Dr Michael Sinclair, Executive Chairman Nicolas Serandour, CEO Tel: +44 20 3617 8728    Stockdale Securities (Nomad & […]

Advanced Oncotherapy (AVO) – Exercise of Options and Issue of Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that is has today issued 36,946 new ordinary shares of 25 pence in the Company to Dr Enrico Vanni, a non-executive director, at a subscription price of 101.5 pence per Ordinary Share (being the closing mid price on 04 November 2016) in […]

Advanced Oncotherapy (AVO) – Directorate Change

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Lord David Evans has stepped down from the Board with immediate effect. In addition, the board of directors of Advanced Oncotherapy intends to appoint Professor Stephen Myers as member of the Board. A further announcement in relation to the […]

Advanced Oncotherapy (AVO) – Result of Open Offer

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, is pleased to announce that the Open Offer announced on 14 October 2016 closed for acceptances at 11am yesterday and received valid acceptances in respect of 3,378,771 Open Offer Shares from Qualifying Shareholders. This represents 84 per cent of the Open […]

Advanced Oncotherapy (AVO) – Industrialisation agreement with Thales

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has finalised the details of the contract for manufacturing the first LIGHT machine with Thales. This forms part of the partnership with Thales that was announced in February 2016.  Thales has selected one of its factories located in France, […]

Advanced Oncotherapy (AVO) – Directorate change

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Nicolas Serandour, Chief Operating Officer and Chief Financial Officer, will become Chief Executive Officer with immediate effect. Michael Sinclair, currently Chief Executive Officer and Executive Chairman, will retain his role as Executive Chairman. Commenting, Dr. Michael Sinclair, Executive Chairman of […]